Research Article
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling
Table 3
Tumor type and clinician and MP-guided therapy recommendation, MP results, and clinical outcomes: prior standard first-line therapy group (PST).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CB = clinical benefit (QOL/PS/general symptoms/weight and imaging results improved or stable); NA = not available; P = progression (QOL/PS/general symptoms/weight and imaging results declined or deteriorated). Ratio of PFS with therapy suggested by MP versus that with prior line of therapy. FOLFIRI, irinotecan + 5-FU + folinic acid; FOLFOX, 5-FU + folinic acid + oxaliplatin; FOLFIRINOX, irinotecan + 5-FU + folinic acid + oxaliplatin; PFS, progression-free survival; PS, performance status; QOL, quality of life. |